Seattle Children's Research Institute and Kineta, Inc.: Alliance for Children's Therapeutics
Tuesday, November 18, 2014
10:00 AM - 10:25 AM
The Alliance for Children's Therapeutics (ACT) is a unique pediatric research and funding collaboration between one of the nation's top-five pediatric research institutions -- Seattle Children's Research Institute -- and Kineta Inc., a leading Seattle-based biotechnology firm. The collaboration is addressing a key problem: Only a small fraction of today's pediatric treatments were developed for -- or tested in -- children. ACT is designed to speed development of new medications for children and teens with lupus nephritis and other autoimmune diseases like multiple sclerosis, Type 1 diabetes, and rheumatoid arthritis.
Charles Magness, President and CEO, Kineta, Inc.
Stephanie Axelrod, Vice President, Community and Strategic Initiatives Seattle Children's Research Institute
View the presentation slides as a PDF